VIDAS B·R·A·H·M·S PCT
bioMérieux Inc
(Durham, NC) recently
received 510(k)
clearance from the
FDA to market VIDAS
B·R·A·H·M·S PCT. The
test will be used
with critically ill patients
on their first
day of admission to
the intensive care
unit (ICU) as an aid to assess their risk for progression to severe
sepsis and septic shock. bioMérieux is the first company in the
United States to launch an automated test measuring procalcitonin
(PCT), a biological marker for bacterial infections. As the
progression of severe bacterial infections is affected by how
early the patient receives appropriate treatment, measuring
PCT levels is valuable in ICUs where sepsis represents a major
health challenge. The VIDAS platform is well-suited to emergency
situations, with VIDAS B·R·A·H·M·S PCT providing test
results in 20 minutes.
For More Information:
www.biomerieux-usa.com
800-682-2666
Polymyxin B Sulfate for Injection
APP Pharmaceuticals Inc
(Schaumburg, IL) recently received
FDA approval for its abbreviated
new drug application for Polymyxin
B Sulfate for Injection, USP, 500,000
units/vial. The product is the generic
equivalent of Bedford Laboratories’
Polymyxin B Sulfate. APP’s
Polymyxin B Sulfate for Injection is
indicated for the treatment of
acute infections caused by susceptible
strains of Pseudomonas
aeruginosa. It may be used topically
or subconjunctivally in the treatment
of infections of the eye caused by susceptible strains of the
same organism. It also may be indicated in the case of serious
infections caused by specific indicated organisms. Polymyxin B
Sulfate for Injections is AP-rated, preservative- and latex-free,
and bar-coded at the individual unit of use.
For More Information:
www.APPpharma.com
